Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(2); doi: 10.25236/AJMHS.2023.040207.

Exploring the mechanism of quercetin on cervical cancer based on network pharmacology and molecular docking


Zhongren Gai1, Bo Tian2, Na Zhang1, Xinyi Yang1

Corresponding Author:
Bo Tian

1Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, China

2Northwest Polytechnic University Hospital, Xi’an, 710072, Shaanxi, China


Cervical cancer is one of the major cancers that endanger women's lives. At present, the means of treatment are still limited. Traditional Chinese medicine and its ingredients, as a new direction, provide new ideas for the treatment of cervical cancer. Quercetin, as the main ingredient in many traditional Chinese medicines, may be a new ingredient in the treatment of cervical cancer. Based on network pharmacology and molecular docking technology, this paper analyzes the mechanism of quercetin in the treatment of cervical cancer, and further explores the modern pharmacological action of quercetin. The related targets of "quercetin" were screened from the TCMSP database; Relevant targets of "cervical cancer" were screened from Genecards database. After the common protein target information of the two was obtained through venny, the protein interaction network was constructed using Cytoscape software, and the hub gene was screened. Use David platform to conduct GO, KEGG and other enrichment analysis on the same target. Finally, molecular docking technology was used to test the accuracy.There are 128 nodes and 911 edges in the PPI network, among which AKT1, TNF, JUN, TP53, IL-6, VEGFA, EGFR, RELA, CASP3 and other targets rank higher. The enrichment analysis results of GO and KEGG showed that the effect of quercetin on cervical cancer mainly involves biological processes such as positive regulation of gene expression, response to drug, positive regulation of translation, DNA-template, etc. The signal path mainly includes AGE-RAGE signaling path in radial applications, TNF signaling path, IL-17 signaling path, etc. Molecular docking results show that quercetin is associated with AKT1, TP53, TNF- α The binding degree of iso-target and quercetin is good. It is enriched in KEGG pathway. It reveals the potential target and mechanism of quercetin acting on cervical cancer, hoping to develop new drugs for treating cervical cancer.


quercetin; network pharmacology; cervical carcinoma; molecular docking; Action mechanism

Cite This Paper

Zhongren Gai, Bo Tian, Na Zhang, Xinyi Yang. Exploring the mechanism of quercetin on cervical cancer based on network pharmacology and molecular docking. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 2: 40-46. https://doi.org/10.25236/AJMHS.2023.040207.


[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68( 1) : 7 - 30.

[2] Li C, Chen J, Zhu J, et al. Plan quality comparison for cervical carcinoma treated with Halcyon and Trilogy intensity-modulated radiotherapy [J]. J Cancer, 2019, 10( 24) : 6135 - 6141.

[3] BABAEI F, MIRZABABAEI M, NASSIRI-ASL M. Quercetin in Food: Possible Mechanisms of Its Effect on Memory [J].Journal of Food Science, 2018, 83(9): 2280-2287. DOI: 10.1111/1750- 3841. 14317.

[4] LI Y, YAO J, HAN C, et al. Quercetin, Inflammation and Immunity [J]. Nutrients, 2016, 8(3): 167. DOI: 10.3390/nu8030167.

[5] Wang Y, Zhang W, Lv Q, et al. The critical role of quercetin in autophagy and apoptosis in HeLa cells [J]. Tumor Biol, 2016,37(1):925-929.

[6] Liu Ruofan, Huang Xing, Yi Fan, etc Based on the network pharmacology, the mechanism of the effect of Naoxueshu oral liquid on the secondary brain injury after cerebral hemorrhage [J]. Journal of Modern Integrated Chinese and Western Medicine, 2021, 30 (30): 3366-3371/3376. DOI: 10.3969/j.issn.1008-8849.2021.30.012

[7] CHEN Q, SPRINGER L, GOHLKE B O, etal. SuperTCM: A biocultural database combining biological path ways and historical linguistic data of Chinese materia medicafor drug development [J]. BiomedPharmacother, 2021, 144:112315. 

[8] Shklar M, Strichman-Almashanu L, Shmueli O, etal. Genetide--Terra incognita discovery endeavor:A new transcriptome focused member of the GeneCards/GeneNote suite of databases [J]. Nucleic Acids Research,2005,33 (Databaseissue):D556-D561.

[9] SZKLARCZYK D, GABLE A L, LYON D, etal. STRING v11: Protein-protein association networks with increased coverage, supporting functional discoverying enome-wide experimental data sets [J]. NucleicAcidsResearch, 2019,47(D1):D607-D613.

[10] Oliveros, J.C. (2007-2015) Venny. An interactive tool for comparing lists with Venn's diagrams. https://bioinfogp.cnb.csic.es/tools/venny/index.html

[11] Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M, Chi KN, Wyatt AW. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2020 Dec;78(6):834-844. doi: 10.1016/j.eururo.2020.04.058. Epub 2020 May 22. PMID: 32451180.

[12] Zhang L, Zhou Q, Qiu Q, Hou L, Wu M, Li J, Li X, Lu B, Cheng X, Liu P, Lu W, Lu Y. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/ DNAJB6/ KLF4/AKT1 axis in ovarian cancer. Mol Cancer. 2019 Oct 17; 18(1):144. doi: 10.1186/s 12943-019- 1080-5. PMID: 31623606; PMCID: PMC6796346.

[13] Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019 Jan; 26(2):199-212. doi: 10.1038/s41418-018-0246-9. Epub 2018 Dec 11. PMID: 30538286; PMCID: PMC6329812.

[14] Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, Shen J, Cai L, Cai X, Chen M. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021 Sep 28; 14(1):157. doi: 10.1186/s13045-021-01169-0. PMID: 34583722; PMCID: PMC8480024.

[15] Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signaling to promote cancer. Mol Cell Biochem. 2021 Feb; 476(2): 585-598. doi: 10.1007/s11010-020-03928-y. Epub 2020 Oct 6. PMID: 33025314.

[16] Muthyalaiah YS, Jonnalagadda B, John CM, Arockiasamy S. Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression. Glycoconj J. 2021 Dec; 38(6):717-734. doi: 10.1007/s10719-021-10031-x. Epub 2022 Jan 22. PMID: 35064413.